IE
LXRX icon

Israel Englander’s Lexicon Pharmaceuticals LXRX Stock Holding History

Israel Englander’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-54,500
Closed -$250K – 7063
2021
Q2 		$250K Buy
+54,500
New +$262K ﹤0.01% 5873

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Israel Englander's LXRX Position: Q2 2026 in Review

Israel Englander reduced its Lexicon Pharmaceuticals (LXRX) stake by 77% in Q2 2026, selling an estimated $7.42M and leaving 1,134,229 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

Israel Englander first reported a position in LXRX in Q4 2014 and has held it in 42 quarters since. The position peaked at $12.9M in Q1 2016. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Israel Englander held 1,134,229 shares of Lexicon Pharmaceuticals worth $2.72M as of Q2 2026.
  • Israel Englander sold 3,810,502 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $7.42M.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3563 holding.
  • Israel Englander first reported a position in Lexicon Pharmaceuticals in Q4 2014 and has held it in 42 quarters since.
  • Israel Englander's Lexicon Pharmaceuticals position peaked at $12.9M in Q1 2016.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.